Tag: Hikma
Hikma delivers strong H1 performance and upgrades Group guidance
Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its interim results for the six months ended 30...
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of...
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has announced that it has recently signed an exclusive licencing agreement with AFT Pharmaceuticals (AFT) for the...
Hikma and Guardant Health sign exclusive partnership agreement to bring transformative...
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces an exclusive agreement with Guardant Health, Inc., a leading precision oncology company. Through the...
Hikma continues strong momentum across the Group and upgrades guidance for...
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.
Riad Mishlawi, Chief Executive Officer...
Good momentum across all businesses and updated Generics guidance
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual...
Hikma delivers a resilient underlying performance in 2022
Amman, Jordan — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its preliminary audited results for the year ended 31...
Hikma and Celltrion Healthcare sign new exclusive licensing agreement for Vegzelma®...
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreement with Celltrion Healthcare Co., Ltd, a global...
Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment...
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces a new exclusive licensing and commercialization agreement with Junshi Biosciences,...
Hikma and Celltrion Healthcare sign exclusive licensing agreement for ustekinumab for...
London, England — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing agreements with Celltrion Healthcare Co., Ltd. for CT-P43 (ustekinumab)....
Hikma and Adalvo Sign Exclusive Licensing Agreement to Commercialise Allergic Rhinitis...
Amman, Jordan — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with Adalvo to commercialise a nasal spray medication...
Hikma’s diversified business delivers resilient H1 performance
London, United Kingdom — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its interim results for the six months ended...
Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the...
London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with Celltrion, Inc. and Celltrion Healthcare, Inc....
Hikma and Melinta Therapeutics sign exclusive licensing agreement for two novel...
London, United Kingdom, 08 May 2021: Hikma Pharmaceuticals PLC (Hikma) and Melinta Therapeutics (Melinta) today announced they have entered into an exclusive licensing agreement...
